Table 2.

The popular vote of all researchers (pro-ACH and non-ACH taken together) toward therapeutic priorities in AD research, tabulated according to participants’ gender. Concerning pharmacological treatments, anti-tau drugs offered more optimism than drug classes inspired by the ACH (anti-Aβ antibodies and/or BACE inhibitors). The top three therapeutic targets at preclinical, prodromal, and established AD were also investigated. Lifestyle interventions were a top-3 therapeutic priority at all stages of AD. Taken as a whole, the data suggest a favorable opinion regarding lifestyle factors and tau protein intervention. Gender differences in therapeutic priority were only significant for preclinical AD, with significantly more males arguing in favor of anti-Aβ strategies at this stage. ^‡Fisher’s exact test was used to compare groups for categorical variables

	All	Female	Male	p ‡
	N = 173	N = 83	N = 80
		(49.70%)	(47.90%)
Optimism towards the following drugs
Anti-tau	97 (61.01%)	50 (66.67%)	40 (53.33%)	0.133
Anti-AB antibodies	62 (38.99%)	24 (32.00%)	33 (44.00%)	0.178
BACE inhibitors	31 (19.50%)	15 (20.00%)	12 (16.00%)	0.671
#1 Therapeutic Priority in preclinical AD				0.020*
Lifestyle factors (diet, smoking, etc.)	74 (43.53%)	39 (46.99%)	31 (39.74%)
Aβ physiology (production, clearance, etc.)	33 (19.41%)	10 (12.05%)	22 (28.21%)
Inflammation, Microglia, and Astrocytes	22 (12.94%)	10 (12.05%)	11 (14.10%)
#1 Therapeutic Priority in prodromal AD				0.060
Lifestyle factors (diet, smoking, etc.)	49 (31.01%)	24 (32.00%)	22 (29.73%)
Tau and NFTs	40 (25.32%)	22 (29.33%)	15 (20.27%)
Inflammation	26 (16.46%)	13 (17.33%)	11 (14.86%)
#1 Therapeutic Priority in established AD				0.928
Tau and NFTs	44 (28.21%)	19 (25.68%)	21 (28.38%)
Lifestyle factors (diet, smoking, etc.)	38 (24.36%)	20 (27.03%)	17 (22.97%)
Inflammation, Microglia, and Astrocytes	29 (18.59%)	14 (18.92%)	13 (17.57%)